Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Tudriqev (vusolimogene oderparepvec-wtpg) - Replimune

sturlimogene erparepvec (RP2) - Replimune

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma (clinicaltrials.gov) - Oct 8, 2026 - P2 | N=34 | Not yet recruiting | Sponsor: Yana Najjar
New P2 trial • Melanoma • Oncology • Solid Tumor • BRAF

http://clinicaltrials.gov/ct2/show/NCT07862530

Oct 8, 2026